LON:FAB Fusion Antibodies (FAB) Share Price, News & Analysis GBX 15.39 +0.39 (+2.60%) As of 08:12 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Fusion Antibodies Stock (LON:FAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fusion Antibodies alerts:Sign Up Key Stats Today's Range 14.51▼ 15.3950-Day Range 10.39▼ 18.9952-Week Range 3.81▼ 21Volume1.02 million shsAverage Volume1.20 million shsMarket Capitalization£17.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue. The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation. Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. The global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021. Read More Receive FAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fusion Antibodies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FAB Stock News HeadlinesFusion Antibodies Secures Major Antibody Humanisation ProjectOctober 8 at 10:52 PM | msn.comFusion Antibodies Secures New Contracts, Boosting Growth ProspectsAugust 27, 2025 | msn.comOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should buy in this market, this token might just be it.October 9 at 2:00 AM | Crypto 101 Media (Ad)Fusion Antibodies Schedules Investor Presentations and Results UpdateAugust 26, 2025 | tipranks.com'This confirms our unique approach': Dunmurry biotechnology company wins US Patent for OptiMAL LibraryAugust 7, 2025 | msn.comFusion Antibodies Share Chat. Chat About FAB Shares - Stock Quote ...August 2, 2025 | lse.co.ukNew commercial strategy sees revenues soar by 71% at Fusion AntibodiesMay 7, 2025 | msn.com£800,000 grant will boost Fusion project to develop new cancer antibodyApril 24, 2025 | msn.comSee More Headlines FAB Stock Analysis - Frequently Asked Questions How have FAB shares performed this year? Fusion Antibodies' stock was trading at GBX 7.16 at the start of the year. Since then, FAB stock has increased by 111.7% and is now trading at GBX 15.16. How were Fusion Antibodies' earnings last quarter? Fusion Antibodies plc (LON:FAB) issued its quarterly earnings results on Thursday, September, 4th. The company reported ($1.80) earnings per share for the quarter. Fusion Antibodies had a negative net margin of 195.95% and a negative trailing twelve-month return on equity of 137.11%. How do I buy shares of Fusion Antibodies? Shares of FAB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Fusion Antibodies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Antibodies investors own include 4D pharma (DDDD), Omega Diagnostics Group (ODX), Tullow Oil (TLW), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA). Company Calendar Last Earnings9/04/2025Today10/08/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:FAB CIKN/A Webfusionantibodies.com Phone+44-28-90432800FaxN/AEmployees48Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£4.10 million Net Margins-195.95% Pretax MarginN/A Return on Equity-137.11% Return on Assets-63.78% Debt Debt-to-Equity Ratio2.40 Current Ratio3.87 Quick Ratio2.36 Sales & Book Value Annual Sales£1.97 million Price / Sales8.78 Cash FlowGBX 1.68 per share Price / Cash Flow9.02 Book ValueGBX 3.51 per share Price / Book4.32Miscellaneous Outstanding Shares113,656,000Free FloatN/AMarket Cap£17.25 million OptionableNot Optionable Beta0.49 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (LON:FAB) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Antibodies plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.